Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI)

BMC Biochemistry

Volumn 10, Issue 1, 2009, Pages

  Valnickova, Zuzana ^a   Thaysen Andersen, Morten ^b   Højrup, Peter ^b   Christensen, Trine ^a   Sanggaard, Kristian W ^a   Kristensen, Torsten ^a   Enghild, Jan J ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRYPSIN; ISOENZYME; PEPTIDE FRAGMENT; POLYSACCHARIDE;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME KINETICS; ENZYME STABILITY; FEMALE; FIBRINOLYSIS; GLYCOSYLATION; HUMAN; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; ANIMAL; CATTLE; CHEMISTRY; COMPARATIVE STUDY; ENZYME SPECIFICITY; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOELECTRIC POINT; KINETICS; METABOLISM; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; TEMPERATURE;

BOVINAE; IXODIDA;

ANIMALS; CARBOXYPEPTIDASE U; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME STABILITY; FIBRINOLYSIS; GLYCOSYLATION; HUMANS; ISOELECTRIC POINT; ISOENZYMES; KINETICS; MOLECULAR WEIGHT; PEPTIDE FRAGMENTS; POLYSACCHARIDES; SUBSTRATE SPECIFICITY; TEMPERATURE; TRYPSIN;

EID: 66149139135     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-10-13     Document Type: Article

References (58)

1. A labile enzyme in fresh human serum interferes with the assay of carboxypeptidase N. D Hendriks S Scharpe M van Sande MP Lommaert, Clin Chem 1989 35 1 177 2910562
2. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. D Hendriks S Scharpe M van Sande MP Lommaert, J Clin Chem Clin Biochem 1989 27 5 277 285 2760564
3. Purification and characterization of a new arginine carboxypeptidase in human serum. D Hendriks W Wang S Scharpe MP Lommaert M van Sande, Biochim Biophys Acta 1990 1034 1 86 92 2328266
4. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. DL Eaton BE Malloy SP Tsai W Henzel D Drayna, J Biol Chem 1991 266 32 21833 21838 1939207
5. Plasma carboxypeptidases as regulators of the plasminogen system. A Redlitz AK Tan DL Eaton EF Plow, J Clin Invest 1995 96 5 2534 2538 7593646 10.1172/JCI118315
6. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. W Wang DF Hendriks SS Scharpe, J Biol Chem 1994 269 22 15937 15944 8195249
7. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. L Bajzar R Manuel ME Nesheim, J Biol Chem 1995 270 24 14477 14484 10.1074/jbc.270.24.14477 7782309
8. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. DV Sakharov EF Plow DC Rijken, J Biol Chem 1997 272 22 14477 14482 10.1074/jbc.272.22.14477 9162090
9. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. LO Mosnier JC Meijers BN Bouma, Thromb Haemost 2001 85 1 5 11 11204587
10. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). BN Bouma JC Meijers, J Thromb Haemost 2003 1 7 1566 1574 10.1046/j.1538-7836.2003.00329.x 12871292
11. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. Z Valnickova IB Thogersen J Potempa JJ Enghild, J Biol Chem 2007 282 5 3066 3076 10.1074/jbc.M606559200 17138567
12. The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays. JL Willemse M Polla DF Hendriks, Anal Biochem 2006 356 1 157 159 10.1016/j.ab.2006.05.020 16797476
13. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. Z Valnickova JJ Enghild, J Biol Chem 1998 273 42 27220 27224 10.1074/jbc.273.42.27220 9765243
14. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. L Bajzar J Morser M Nesheim, J Biol Chem 1996 271 28 16603 16608 10.1074/jbc.271.28.16603 8663147
15. Activation and characterization of procarboxypeptidase B from human plasma. AK Tan DL Eaton, Biochemistry 1995 34 17 5811 5816 10.1021/bi00017a012 7727441
16. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. SS Mao CM Cooper T Wood JA Shafer SJ Gardell, J Biol Chem 1999 274 49 35046 35052 10.1074/jbc.274.49. 35046 10574983
17. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. PF Marx PE Dawson BN Bouma JC Meijers, Biochemistry 2002 41 21 6688 6696 10.1021/bi015982e 12022872
18. Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation. Z Valnickova T Christensen P Skottrup IB Thogersen P Hojrup JJ Enghild, Biochemistry 2006 45 5 1525 1535 10.1021/bi051956v 16445295
19. Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein. Z Valnickova IB Thogersen S Christensen CT Chu SV Pizzo JJ Enghild, J Biol Chem 1996 271 22 12937 12943 10.1074/jbc.271.22.12937 8662763
20. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. W Wang MB Boffa L Bajzar JB Walker ME Nesheim, J Biol Chem 1998 273 42 27176 27181 10.1074/jbc.273.42.27176 9765237
21. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. MB Boffa R Bell WK Stevens ME Nesheim, J Biol Chem 2000 275 17 12868 12878 10.1074/jbc.275.17.12868 10777585
22. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. PF Marx TM Hackeng PE Dawson JH Griffin JC Meijers BN Bouma, J Biol Chem 2000 275 17 12410 12415 10.1074/jbc.275.17.12410 10777524
23. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. WD Campbell E Lazoura N Okada H Okada, Microbiol Immunol 2002 46 2 131 134 11939578
24. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. T Myles T Nishimura TH Yun M Nagashima J Morser AJ Patterson RG Pearl LL Leung, J Biol Chem 2003 278 51 51059 51067 10.1074/jbc.M306977200 14525995
25. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. EA te Velde GT Wagenaar A Reijerkerk M Roose-Girma IH Borel Rinkes EE Voest BN Bouma MF Gebbink JC Meijers, J Thromb Haemost 2003 1 10 2087 2096 10.1046/j.1538-7836.2003.00404.x 14521589
26. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. Y Hori EC Gabazza Y Yano A Katsuki K Suzuki Y Adachi Y Sumida, J Clin Endocrinol Metab 2002 87 2 660 665 10.1210/jc.87.2.660 11836301
27. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. Y Yano N Kitagawa EC Gabazza K Morioka H Urakawa T Tanaka A Katsuki R Araki-Sasaki Y Hori K Nakatani, J Clin Endocrinol Metab 2003 88 2 736 741 10.1210/jc.2002-020691 12574207
28. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. O Hataji O Taguchi EC Gabazza H Yuda CN D'Alessandro-Gabazza H Fujimoto Y Nishii T Hayashi K Suzuki Y Adachi, Am J Hematol 2004 76 3 214 219 10.1002/ajh.20079 15224354
29. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. DH Van Thiel M George J Fareed, Thromb Haemost 2001 85 4 667 670 11341503
30. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. JA Kremer Hovinga RF Franco MA Zago H Ten Cate RG Westendorp PH Reitsma, J Thromb Haemost 2004 2 1 54 57 10.1111/j.1538-7836.2004.00557.x 14717966
31. A novel approach to arterial thrombolysis. P Klement P Liao L Bajzar, Blood 1999 94 8 2735 2743 10515877
32. Molecular cloning and partial characterization of rat procarboxypeptidase R and carboxypeptidase N. T Kato H Akatsu T Sato S Matsuo T Yamamoto W Campbell N Hotta N Okada H Okada, Microbiol Immunol 2000 44 8 719 728 11021404
33. Characterization of mouse thrombin-activatable fibrinolysis inhibitor. PF Marx GT Wagenaar A Reijerkerk MJ Tiekstra AG van Rossum MF Gebbink JC Meijers, Thromb Haemost 2000 83 2 297 303 10739389
34. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis. JA Bjorkman TI Abrahamsson VK Nerme CJ Mattsson, Thromb Res 2005 116 6 519 524 10.1016/j.thromres.2005.02.009 16181987
35. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)-a comparative study assessing the biological equivalence of rat, murine and human TAFI. K Hillmayer A Macovei D Pauwels G Compernolle PJ Declerck A Gils, J Thromb Haemost 2006 4 11 2470 2477 10.1111/j.1538-7836.2006.02224.x 17002650
36. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. X Wang PL Smith MY Hsu ML Ogletree WA Schumacher, J Thromb Haemost 2006 4 2 403 410 10.1111/j.1538-7836. 2006.01703.x 16420573
37. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice. M Nagashima ZF Yin GJ Broze Jr J Morser, Front Biosci 2002 7 d556 568 10.2741/nagashim 11815293
38. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. M Nagashima ZF Yin L Zhao K White Y Zhu N Lasky M Halks-Miller GJ Broze Jr WP Fay J Morser, J Clin Invest 2002 109 1 101 110 11781355
39. Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). PJ Barbosa Pereira S Segura-Martin B Oliva C Ferrer-Orta FX Aviles M Coll FX Gomis-Ruth J Vendrell, J Mol Biol 2002 321 3 537 547 10.1016/S0022-2836(02)00648-4 12162965
40. Isolation and characterization of pancreatic procarboxypeptidase B and carboxypeptidase B of the African lungfish. GR Reeck H Neurath, Biochemistry 1972 11 21 3947 3955 10.1021/bi00771a018 5079891
41. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. PF Marx TH Brondijk T Plug RA Romijn W Hemrika JC Meijers EG Huizinga, Blood 2008 112 7 2803 2809 10.1182/blood-2008-03-146001 18559974
42. The Crystal Structure of Thrombin-activable Fibrinolysis Inhibitor (TAFI) Provides the Structural Basis for Its Intrinsic Activity and the Short Half-life of TAFIa. K Anand I Pallares Z Valnickova T Christensen J Vendrell KU Wendt HA Schreuder JJ Enghild FX Aviles, J Biol Chem 2008 283 43 29416 29423 10.1074/jbc.M804003200 18669641
43. A carboxypeptidase inhibitor from the tick Rhipicephalus bursa: isolation, cDNA cloning, recombinant expression, and characterization. JL Arolas J Lorenzo A Rovira J Castella FX Aviles CP Sommerhoff, J Biol Chem 2005 280 5 3441 3448 10.1074/jbc.M411086200 15561703
44. The three-dimensional structures of tick carboxypeptidase inhibitor in complex with A/B carboxypeptidases reveal a novel double-headed binding mode. JL Arolas GM Popowicz J Lorenzo CP Sommerhoff R Huber FX Aviles TA Holak, J Mol Biol 2005 350 3 489 498 10.1016/j.jmb.2005.05.015 15961103
45. Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis. L Sanglas Z Valnickova JL Arolas I Pallares T Guevara M Sola T Kristensen JJ Enghild FX Aviles FX Gomis-Ruth, Mol Cell 2008 31 4 598 606 10.1016/j.molcel.2008.05.031 18722183
46. Biochemical Importance of Glycosylation in Thrombin Activatable Fibrinolysis Inhibitor. K Buelens K Hillmayer G Compernolle PJ Declerck A Gils, Circ Res 2007 102 3 295 301 10.1161/CIRCRESAHA.107.157099 18063813
47. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. L Zhao J Morser L Bajzar M Nesheim M Nagashima, Thromb Haemost 1998 80 6 949 955 9869166
48. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis. W Knecht J Willemse H Stenhamre M Andersson P Berntsson C Furebring A Harrysson AC Hager BM Wissing D Hendriks, Febs J 2006 273 4 778 792 10.1111/j.1742-4658.2006.05110.x 16441664
49. Comparative evaluation of stable TAFIa variants importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability. E Ceresa M De Maeyer A Jonckheer M Peeters Y Engelborghs PJ Declerck A Gils, J Thromb Haemost 2007 5 10 2105 12 10.1111/j.1538-7836.2007.02720.x 17666015
50. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. GJ Brouwers HL Vos FW Leebeek S Bulk M Schneider M Boffa M Koschinsky NH van Tilburg ME Nesheim RM Bertina, Blood 2001 98 6 1992 1993 10.1182/blood.V98.6.1992 11565542
51. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. M Schneider M Boffa R Stewart M Rahman M Koschinsky M Nesheim, J Biol Chem 2002 277 2 1021 1030 10.1074/jbc.M104444200 11684677
52. Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor. PF Marx SR Havik BN Bouma JC Meijers, J Thromb Haemost 2005 3 6 1293 1300 10.1111/j.1538-7836.2005.01322.x 15946220
53. Plasminogen: purification from human plasma by affinity chromatography. DG Deutsch ET Mertz, Science 1970 170 962 1095 1096 10.1126/science.170.3962. 1095 5475635
54. Evaluation of three sodium dodecyl sulphate-polyacrylamide gel electrophoresis buffer systems. AF Bury, J Chromatogr 1981 213 491 450 10.1016/S0021-9673(00)80500-2
55. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. P Matsudaira, J Biol Chem 1987 262 21 10035 10038 3611052
56. Assay of carboxypeptidase N activity in serum by liquid-chromatographic determination of hippuric acid. D Hendriks S Scharpe M van Sande, Clin Chem 1985 31 12 1936 1939 3933850
57. Resistance of gammaA/gamma' fibrin clots to fibrinolysis. LA Falls DH Farrell, J Biol Chem 1997 272 22 14251 14256 10.1074/jbc.272.22.14251 9162058
58. Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrix-assisted laser desorption/ionization mass spectrometry. J Gobom E Nordhoff E Mirgorodskaya R Ekman P Roepstorff, J Mass Spectrom 1999 34 2 105 116 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4 10093212